5 edition of Current Issues In Platelet Transfusion Therapy And Platelet Alloimmunity found in the catalog.
by American Association of Blood Banks
Written in English
|The Physical Object|
|Number of Pages||306|
Content: The initial sections discuss cellular blood products and the clinical problems that dictate their use, including red cell transfusion for autoimmune disease and hemoglobinopathy. Platelet and granulocyte transfusion therapy are also covered. A detailed section describes various aspects of the management of coagulopathy and disorders of by: 1. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
Medicine: Blood Transfusion Side effects can include allergic reactions such as anaphylaxis, infection, and lung injury. Bacterial infections are relatively more common with platelets as . The purpose of the guideline is to provide updated recommendations regarding the use of platelet transfusion in people with cancer. 1 ASCO first published a guideline on platelet transfusion in people with cancer in 2 The guideline recognized the important role of platelet transfusion in the prevention and treatment of bleeding in patients with treatment-related thrombocytopenia but also Cited by: 3.
A Review of Current Practice in Transfusion Therapy Contrada, Emily AJN The American Journal of Nursing: May - Volume - Issue 5 - p 45, Current Issues in Platelet Transfusion Therapy and Platelet Alloimmunity Edited by Thomas S. Kickler, MD and Jay H. Herman, MD Platelet-rich plasma therapy - Platelet-rich plasma therapy is one such technique where the internal cells guarantee that the recuperating procedure is point of departure from all the trauma caused earlier and.
Action taken by Government on the recommendations contained in the third Report of the Committee on Public Undertakings (third Lok Sabha)
Individual & Family Markets, 5E
Oceanographic observations in the Canadian Basin, Arctic Ocean, April-May, 1962
Becker the World of the Cell 1/E 1996 and Bloom Laboratory DNA Science 1/E 1996 Bundle
All honorable men
Health care integration
Haynes Land-Rover (Diesel Owners Workshop Manual, 58-85)
Dress Regulations for the Army
Book budgets, community college libraries, and lotus 1-2-3.
Searchers of the sea
Sudden infant death syndrome
Sonate 1re = Sonata 1
NBS publications listing
Current Issues in Platelet Transfusion Therapy and Platelet Alloimmunity: Medicine & Health Science Books @ COVID Resources. Reliable information about the coronavirus (COVID) is available from the World Health Organization (current situation, international travel).Numerous and frequently-updated resource results are available from this ’s WebJunction has pulled together information and resources to assist library staff as they consider how to handle coronavirus.
Current Issue; All Issues; Cover Gallery; Follow journal. Alert; RSS Feeds. Most recent (RSS) Most cited (RSS) BOOK REVIEWS. Current Issues in Platelet Transfusion Therapy and Platelet Alloimmunity.
Lawrence D. Petz MD; Pages: ; First Published. CURRENT ISSUES IN PLATELET TRANSFUSION THERAPY Quality control It is not satisfactory to simply count the number of platelets and leukocytes to assure adequate platelet quality in a PC, particularly after a storage by: 2.
This review will examine the issues, risks, and costs associated with platelet transfusion therapy. Issues in Platelet Transfusion Practices Prophylactic Versus Therapeutic Regimens There is a long-standing debate on whether to transfuse platelets prophylactically to prevent bleeding in thrombocytopenic patients or to wait until bleeding occurs Cited by: After platelets are isolated from red blood cells in whole blood, the red blood cells are stored at 1°C to 6°C to extend their posttransfusion survivability.
9 For the purpose of transfusion therapy, there are four different components within whole blood—red blood cells, plasma, cryoprecipitate, and platelets—each of which can be modified to help achieve goal-directed outcomes while mitigating the risk of adverse.
Introduction. Platelet transfusions have contributed to the revolutionary modern treatment of thrombocytopenia in patients with cancer and hematological malignancies receiving chemotherapy over the past 50 years. However, despite the long-term application of platelet transfusion in therapeutics, all aspects of their optimal use have not been definitively determined yet.
Platelet (PLT) transfusion is indicated either prophylactically or therapeutically to reduce the risk of bleeding or to control active bleeding.
Significant uncertainty exists regarding the appropriate use of PLT transfusion and the optimal threshold for transfusion in various by: The role of platelet transfusions in the management of immune thrombocytopenic purpura (ITP) is debatable.
The international consensus guidelines on the diagnosis and management of ITP (Blood, ) recommends that platelet transfusions be reserved for use when an urgent restoration in platelet count is needed, such as for patients who are bleeding and those preparing for by: 3.
The use of a unit of apheresis platelets as an adult dose was established in patients with cancer over decades of use and tested in the PLADO (Platelet Dose Trial) randomized controlled trial, but only in the context of prophylactic platelet transfusion to prevent World Health Organization grade 2 bleeding in hypoproliferative thrombocytopenia Cited by: To resolve these issues, the National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), the Center for Drugs and Biologics of the Food and Drug Administration, and the NIH Office of Medical Applications of Research convened a Consensus Development Conference on Platelet Transfusion Therapy on October The study and management of this complication is often disappointing.
In summary, although it is a widespread practice, platelet transfusion has still many controversial and unknown issues. The objective of this article is to review the current evidence on platelet transfusion practices, focusing on the controversial issues and challenges.
Platelet transfusion is not indicated for patients with chronic DIC or for whom there is no bleeding. In general, platelet transfusion is not indicated in immune thrombocytopenia unless there is clinically significant bleeding.
Clinical Indications for prophylactic platelet transfusion for prevention of File Size: KB. TRANSFUSION Transfusion Therapy Clinical Principles and Practice excels most as a superb practical guide for real-world transfusion medicine.
It is divided into five sections on transfusion in clinical practice, blood components and derivatives, preventing 5/5(1). Wahl S, Quirolo KC. Current issues in blood transfusion for sickle cell disease. Curr Opin Pediatr. Feb. 21(1) The Trial to Reduce Alloimmunization to Platelets Study Group.
Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. Platelets - winner of a Highly Commended BMA Medical Book Award for Internal Medicine - is the definitive current source of state-of-the-art knowledge about platelets and covers the entire field of platelet biology, pathophysiology, and clinical medicine.
Recently there has been a rapid expansion of knowledge in both basic biology and the clinical approach to platelet-related diseases Book Edition: 3. Pretreat with IVIG before transfusion. IVIG pretreatment can result in successful increments after platelet transfusion in patients who are alloimmunized.
T1 - Current issues with platelet transfusion in patients with cancer. AU - McCullough, Jeffrey. PY - /1/1. Y1 - /1/1.
N2 - For the past 30 years, platelet transfusions have been used in the treatment of thrombocytopenia caused by decreased production, inadequate function, or increased destruction of by: The numerous factors associated with poor recovery and survival of transfused platelets (non-immune and immune), and the diagnosis, management, and prevention of alloimmune refractoriness to platelet transfusion will be reviewed here.
General issues related to platelet transfusion. Patients who had normal platelet function in the first place (not compliant or not a responder to the therapy) were excluded. All patients had initial platelet counts greater than K/ml.
They underwent platelet transfusion for management of hemorrhagic shock, intracranial hemorrhage, or an emergent neurosurgical procedure. Here are the factoids. Platelet transfusion refractoriness is defined as an insufficient post-transfusion PLT count increment.
Usually it is defined as two or more consecutive CCIs of transfusion of ABO-identical PLT concentrates less than 3 days old (fig. 2) .Cited by: 8. Transfusion. Jun. 33(6) Wahl S, Quirolo KC.
Current issues in blood transfusion for sickle cell disease. Curr Opin Pediatr. Feb. 21(1) The Trial to Reduce Alloimmunization to Platelets Study Group. Platelet Therapy. Current Status and Future Trends Platelet Therapy.
Current Status and Future Trends Lozano, Miguel This book, with editors from both sides of the Atlantic, is an authoritative overview of the current knowledge about the preparation, storage, and transfusion of platelet concentrates.
The editors have recruited an international group of authors, Author: Lozano, Miguel.